Bayesian estimation of cost-effectiveness ratios from clinical trials
Related Experiment Video
Updated: Oct 13, 2026

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
Published on: September 10, 2018
D F Heitjan1, A J Moskowitz, W Whang
1Division of Biostatistics, International Center for Health Outcomes and Innovation Research, Columbia University, New York, NY 10032, USA. dfh5@columbia.edu
Abstract:
Estimation of the incremental cost-effectiveness ratio (ICER) is difficult for several reasons: treatments that decrease both cost and effectiveness and treatments that increase both cost and effectiveness can yield identical values of the ICER; the ICER is a discontinuous function of the mean difference in effectiveness; and the standard estimate of the ICER is a ratio. To address these difficulties, we have developed a Bayesian methodology that involves computing posterior probabilities for the four quadrants and separate interval estimates of ICER for the quadrants of interest. We compute these quantities by simulating draws from the posterior distribution of the cost and effectiveness parameters and tabulating the appropriate posterior probabilities and quantiles. We demonstrate the method by re-analysing three previously published clinical trials.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Bioequivalence Data: Statistical Interpretation
Odds Ratio
Kaplan-Meier Approach
Hazard Ratio
For example, in a clinical trial evaluating a...

